Phase 3 Hepatitis B Trial, Recruiting NCT05905172 Sponsor: Beijing Continent Pharmaceutical Co, Ltd. Condition: Hepatitis B
Back to Hepatitis B

Phase 3 Hepatitis B Trial, Recruiting

NCT05905172
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must have already taken part in the related Phase III trial (NCT05115942), completed the full treatment course, and attended the final visit.
  • You must be willing to take part voluntarily, be able to communicate well with the research team, follow all study requirements, and sign a consent form showing you understand what the trial involves, including its possible benefits and risks.

Who may not be able to join:

  • You experienced one of certain serious health events during the Phase III trial — for example, developing cirrhosis, liver cancer, serious liver complications (such as fluid build-up in the abdomen, internal bleeding, a type of kidney failure, brain problems caused by liver disease, or blood clots in the liver's main vein), a liver transplant, or death related to liver disease (confirm with trial site for the full list relevant to your situation).
  • You have been diagnosed with a cancer other than liver cancer, and doctors expect you to live less than one year.
  • The trial team has any concern that taking part could affect your safety, affect the trial results, or that something may make it difficult for you to give proper consent or follow the trial's requirements (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Lungen Lu, Dr, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phone: +86-13501209210

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Beijing Continent Pharmaceutical Co, Ltd.
Registry
ClinicalTrials.gov
Start date
12 August 2023
Est. completion
20 June 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Cumulative incidence of clinical endpoint events (defined as the occurrence of any clinical endpoint event).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov